Biotech News

Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference

Tango Therapeutics (TNGX)Tango TherapeuticsConference / presentation

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at Guggenheim’s 3 rd Annual Healthcare Innovation Conference on

Related news

Tango Therapeutics

Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen...

Recent company news

Stock data

Close
22.71 USD
Market cap
3.11B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States